|
DROTAVERIN HYDROCHLORIDE |
| 6,7,3',4'-Tetraethoxy-1-benzal-1,2,3,4-tetrahydroisoquinoline hydrochloride; Drotaverin HCl; Drotaverine hydrochloride; Drotaverinium chloride; Isodihydroperparine hydrochloride; Tetraspasmin-Lefa; 1-(3,4-Diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride; (1Z)-1-((3,4-diethoxyphenyl)methylidene)-6,7-diethoxy-3,4-dihydro-2H-isoquinoline hydrochloride; |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
985-12-6, 14009-24-6(parent) |
|
EINECS RN |
|
|
FORMULA |
C24H31NO4.HCl |
|
MOLE WEIGHT |
433.97 |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
yellowish and greenish shade crystalline powder |
|
MELTING POINT |
208 - 211 C |
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
|
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. May discolor on exposure to light. |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents |
| DECOMPOSITION PRODUCTS |
Carbon monoxide, Carbon dioxide, Nitrogen oxides, Hydrogen chloride |
| POLYMERIZATION | Has not been reported |
|
NFPA RATINGS |
Health:2 , Flammability:0 , Reactivity:1 |
|
|
| SAFETY |
|
|
HAZARD NOTES |
Harmful if swallowed. Target organ(s): Smooth muscle. |
|
EYE |
May cause eye irritation. |
|
SKIN |
May be harmful if absorbed through skin. May cause skin irritation. |
|
INGESTION |
Harmful if swallowed. |
|
INHALATION |
Harmful if inhaled. Material may be irritating to mucous membranes and respiratory tract. |
|
CHRONIC |
|
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
6.1 |
| HAZARD CLASS |
1544 |
| PACKING GROUP |
III |
| HAZARD SYMBOL |
XN |
|
RISK PHRASES |
22 |
|
SAFETY PHRASES |
22 |
|
|
| EXTERNAL LINKS & GENERAL INFORMATION |
|
Pharmacology: Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of
cerebral and peripheral ischemia associated with arterial spasm and myocardial
ischemia complicated by arrhythmias. The main actions of Papaverine are exerted
on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the
heart muscle to depress conduction and prolong the refractory period. Papaverine
relaxes various smooth muscles. This relaxation may be prominent if spasm
exists. The muscle cell is not paralyzed by Papaverine and still responds to
drugs and other stimuli causing contraction. The antispasmodic effect is a
direct one, and unrelated to muscle innervation. Papaverine is practically
devoid of effects on the central nervous system. Papaverine relaxes the smooth
musculature of the larger blood vessels, especially coronary, systemic
peripheral, and pulmonary arteries. Mechanism of Action: Perhaps by its direct vasodilating action on cerebral blood vessels,
Papaverine increases cerebral blood flow and decreases cerebral vascular
resistance in normal subjects; oxygen consumption is unaltered. These effects
may explain the benefit reported from the drug in cerebral vascular
encephalopathy. (http://www.drugbank.ca/) Paperverine is a smooth muscle relaxant. It belongs to the group of medicines called vasodilators. Vasodilators cause blood vessels to expand, thereby increasing blood flow, and are used to treat problems resulting from poor blood circulation. Papaverine is an opium alkaloid found in the opium poppy, but papaverine differs in both structure and pharmacological action from the other opium alkaloids. (http://www.hull.ac.uk/) Drotaverine hydrochloride is an analogue of papaverine with smooth muscle relaxant properties. It is a non-anticholinergic antispasmodic, which selectively inhibits phosphodiesterase IV and is accompanied by a mild calcium channel-blocking effect. Adverse effects with drotaverine hydrochloride, such as hypotension, vertigo, nausea, and palpitation, are mostly mild. It can be supposed that intravenous drotaverine hydrochloride might be a feasible antimotility alternative to intravenous hyoscine-N-butylbromide in ERCP. But there is no clear evidence to recommend the use of drotaverine hydrochloride as an antispasmodic during ERCP. The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP. The effects of drotaverine hydrochloride on facilitative cannulation and its adverse effects were also compared to hyoscine-N-butylbromide. (http://clinicaltrials.gov/)
|
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
yellowish and greenish shade crystalline powder |
|
ASSAY |
98.5 - 100.5% |
|
MELTING POINT |
208 - 211 C |
|
HEAVY METALS |
20ppm max |
|
SOLVENT RESIDUE |
0.1% max |
|
RELATED SUBSTANCES |
1..0% max (total), 0.5% max (individual) |
|
RESIDUE ON IGNITION |
0.1% max |
|
LOSS ON DRYING |
5.0% max |
| pH |
3.0 - 5.5 |
|
|
| PACKING |
|
|
|
|
| PRICE |
| Papaverine hydrochloride 5kgs: U$2,500.- , Drotaverine hydrochloride 5kgs: U$1,900.- |